AVTX Avalo Therapeutics, Inc.

Nasdaq avalotx.com


$ 14.57 $ -0.70 (-4.54 %)    

Thursday, 13-Nov-2025 15:59:54 EST
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 14.73
$ 15.31
$ 14.16 x 70
$ 15.81 x 59
-- - --
$ 3.39 - $ 19.41
262,836
na
267.11M
$ 0.91
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-06-2025 09-30-2025 10-Q
2 08-07-2025 06-30-2025 10-Q
3 05-12-2025 03-31-2025 10-Q
4 03-20-2025 12-31-2024 10-K
5 11-07-2024 09-30-2024 10-Q
6 08-12-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-29-2024 12-31-2023 10-K
9 11-09-2023 09-30-2023 10-Q
10 08-03-2023 06-30-2023 10-Q
11 05-04-2023 03-31-2023 10-Q
12 03-29-2023 12-31-2022 10-K
13 11-07-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 03-02-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-02-2021 06-30-2021 10-Q
19 05-13-2021 03-31-2021 10-Q
20 03-08-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-06-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-11-2020 12-31-2019 10-K
25 11-14-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-18-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-11-2018 03-31-2018 10-Q
32 04-02-2018 12-31-2017 10-K
33 11-07-2017 09-30-2017 10-Q
34 08-14-2017 06-30-2017 10-Q
35 05-09-2017 03-31-2017 10-Q
36 03-14-2017 12-31-2016 10-K
37 11-08-2016 09-30-2016 10-Q
38 08-15-2016 06-30-2016 10-Q
39 05-16-2016 03-31-2016 10-Q
40 03-23-2016 12-31-2015 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 avalo-therapeutics-q3-eps-219-misses-161-estimate

Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(2.19) per share which missed the analyst consensus estimate of ...

Core News & Articles

Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The ...

 why-merus-shares-are-trading-higher-by-38-here-are-20-stocks-moving-premarket

Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus fo...

 hc-wainwright--co-maintains-buy-on-avalo-therapeutics-raises-price-target-to-25

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and raises the pric...

 cantor-fitzgerald-initiates-coverage-on-avalo-therapeutics-with-overweight-rating

Cantor Fitzgerald analyst Prakhar Agrawal initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Overweight rating.

 avalo-therapeutics-q2-eps-192-misses-142-estimate-cash-cash-equivalents-and-short-term-investments-were-1133m-as-of-june-30

Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of ...

 hc-wainwright--co-assumes-avalo-therapeutics-at-buy-announces-price-target-of-15

HC Wainwright & Co. analyst Mitchell Kapoor assumes Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Pri...

 avalo-therapeutics-represents-an-attractive-pure-play-analyst-initiates-coverage-with-over-300-stock-upside

Avalo Therapeutics' AVTX-009 is advancing in hidradenitis suppurativa, with Phase 2 data expected in 2026. Stifel initiates...

 jefferies-initiates-coverage-on-avalo-therapeutics-with-buy-rating-announces-price-target-of-23

Jefferies analyst Kambiz Yazdi initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price ...

 stifel-initiates-coverage-on-avalo-therapeutics-with-buy-rating-announces-price-target-of-36

Stifel analyst Alex Thompson initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Ta...

 hc-wainwright--co-reiterates-neutral-on-avalo-therapeuticsto-neutral

HC Wainwright & Co. analyst Edward White reiterates Avalo Therapeutics (NASDAQ:AVTX) from Neutral to Neutral.

 piper-sandler-initiates-coverage-on-avalo-therapeutics-with-overweight-rating-announces-price-target-of-48

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Overweight rating and ann...

 btig-initiates-coverage-on-avalo-therapeutics-with-buy-rating-announces-price-target-of-40

BTIG analyst Julian Harrison initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Ta...

 lucid-capital-markets-initiates-coverage-on-avalo-therapeutics-with-buy-rating-announces-price-target-of-24

LUCID CAPITAL MARKETS analyst Dev Prasad initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and annou...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION